Northern Trust
MAZE

Northern Trust’s Maze Therapeutics MAZE Stock Holding History

Northern Trust’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.31M Buy
211,382
+35,123
+20% +$1.55M ﹤0.01% 2338
2025
Q4 		$7.3M Sell
176,259
-631
-0.4% -$21.7K ﹤0.01% 2250
2025
Q3 		$4.59M Buy
176,890
+91,344
+107% +$1.54M ﹤0.01% 2548
2025
Q2 		$1.05M Buy
85,546
+14,708
+21% +$153K ﹤0.01% 3362
2025
Q1 		$780K Buy
+70,838
New +$853K ﹤0.01% 3384

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Northern Trust's MAZE Position: Q1 2026 in Review

Northern Trust increased its Maze Therapeutics (MAZE) stake by 20% in Q1 2026, buying an estimated $1.55M and bringing the position to 211,382 shares worth $6.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2338.

Northern Trust first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.3M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Northern Trust held 211,382 shares of Maze Therapeutics worth $6.31M as of Q1 2026.
  • Northern Trust bought 35,123 Maze Therapeutics shares in Q1 2026, an estimated $1.55M.
  • Maze Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2338 holding.
  • Northern Trust first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Northern Trust's Maze Therapeutics position peaked at $7.3M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.